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Legionella pneumophila is a facultative intracellular bacterial pathogen that is the
causative agent ofLegionnaires'disease, a serious and often fatal form ofpneumonia
(1). L. pneumophila causes 80-85% ofthe cases ofLegionnaires' disease (2). Patients
with Legionnaires' disease develop bothhumoralandcell-mediated immune responses
to L. pneumophila (3-5). Cell-mediated immunity appears to play a vital role in host
defense. Activatedhumanmonocytes andalveolarmacrophages inhibit the intracel-
lular multiplication of L. pneumophila (5-9). Humoral immunity appears to play a
lesser role in host defense (3-4).
The guinea pig is an excellent animal model for the study of Legionnaires' dis-
ease. When exposed to aerosols containing L. pneumophila, guinea pigs develop a
pneumonic illness that is clinically and pathologically similar to Legionnaires' dis-
ease in humans (10-14).
Previous studiesfrom thislaboratoryhave demonstrated thatguinea pigsimmunized
with a sublethalaerosol doseofwild-type L. pneumophila, orwith an aerosolizeddose
ofan avirulent mutant L. pneumophila, develop humoral and cell-mediated immune
responses to wild-type L. pneumophila membrane antigens, and protective immunity
againstchallengewith alethal aerosol dose ofLpneumophila(15, 16). Moreover, previous
work from this laboratory has demonstrated that guinea pigs immunized with an
aerosolized sublethal dose of L. pneumophila develop a strong cell-mediated immune
response to the major secretory protein (MSP)' of L. pneumophila as demonstrated
by invitro lymphocyte proliferation(17). MSP is themost abundant proteinreleased
by L. pneumophila into growth medium(18). It is aprotease with an apparent molec-
ularweight of39,000 whoseenzymatic activity isinhibitedby EI7TA. An EDTA-inhib-
itable protease ofcomparable size has been isolated from another strain of L. pneu-
mophila (19).
In the present study, we have examined the capacity of MSP to induce immune
responses in theguinea pig. We shalldemonstrate thatvaccinationwith this protein
induces humoral and cell-mediated immune responses. We shall also demonstrate
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that, remarkably, vaccination with this single molecule of L. pneumophila induces
protective immunity against lethal aerosol challenge.
Materials and Methods
Media .
￿
Each liter of yeast extract broth (YEB) was prepared with 10 g of ACES (Sigma
Chemical Co., St. Louis, MO), 10 g yeast extract (Difco Laboratories, Detroit, MI), 0.4 g
L-cysteine HCl (Fisher Scientific Co., Fairlawn, NJ), and 0.25 g ferric pyrophosphate (Sigma
Chemical Co.) adjusted to a pH of 6.9 with 10 N KOH, and filter sterilized.
RPMI 1640 with L-glutamine (Gibco Laboratories, Grand Island, NY) was mixed with
penicillin (100 Urn]) and streptomycin (100 Wg/ml) (Gibco Laboratories). Egg yolk buffer
(EYB) with or without 1% BSA (Miles Laboratories Inc., Naperville, IL) was prepared as
previously described (1).
Agar .
￿
Modified charcoal yeast extract agar (CYEA) was prepared as described (1). Modified
CYEA without cysteine and tryptic soy agar with 5% sheep blood were used to assay for
contamination of non-Legionella species.
Bacteria.
￿
L. pneumophila, Philadelphia 1 strain (serogroup 1), was grown in embryonated
hen's eggs; harvested; tested for viability; tested for the presence ofcontaminating bacteria;
passed one time only on CYEA; washed with EYB; flash frozen in aliquots of 10" CFU/ml
and stored at -70°C (1). Before use in the aerosol inoculation system, a stock preparation
of bacteria was diluted in EYB to the desired concentration.
Purification ofMSP.
￿
L. pneumophila from a stock preparation was grown on CYEA plates,
suspended in YEB, and inoculated into 2 L Erlenmeyer flasks containing 500 ml of prewarmed
YEB. The optical density (OD) of the inoculated media at 540 nm on a spectrophotometer
(Junior model 35; Perkin-Elmer Corp., Oak Brook, IL) was approximately 0.05. The bac-
teria were grown for -20 h at 37°C on a rotating platform at 120 rpm to an OD of -1.0.
The culture was checked for the presence of contaminants by light microscopy, and demon-
strated free of contaminants by inoculating CYEA, CYEA without L-cysteine, and sheep
blood agar. The bacteria were then pelleted by centrifugation at 16,000 g for 10 min at 4°C.
The supernatant fluid was decanted and filtered sequentially through 0.45 itm and 0.2 /Am
Tuffryn low protein binding filters (Gelman Sciences Inc., Ann Arbor, MI) to remove re-
sidual bacteria. The filtrate was saturated with ammonium sulfate grade 1 to a level of45%,
stirred 1 h at 4°C, and the precipitate that formed was pelleted by centrifugation at 16,000 g
for 35 min at 4°C and discarded. The supernate was brought to 95% saturation with ammo-
nium sulfate, stirred gently overnight at 4°C, and the precipitate that formed was pelleted
by centrifugation as above. The supernatant was discarded and the MSP-rich pellet was
resuspended in 0.025 M Bis Tris, 0.01 M EDTA, 0.15 M NaCl, pH 5.9 (BEN), and dialyzed
at 4°C overnight in a Spectrapor dialysis membrane (Spectrum Medical Industries, Los An-
geles, CA) with a 6-8,000 mot wt cut-off against 1 L of BEN. The dialyzed MSP-rich fluid
was then applied to a 50 x 2.5 cm Sephacryl S-200 column (Pharmacia Fine Chemicals,
Piscataway, NJ), eluted in BEN at a flow rate of 8 ml/h, and fractions containing MSP were
identified by SDS-PAGE (20). These fractions were pooled and filter concentrated on ice with
an Amicon Corp. (Danvers, MA) filter unit using a filter with a nominal mot wt limit of
30,000 (Millipore, Bedford, MA). The concentrated semipurified protein was applied to a
2.5 x 13 cm Sepharose CL-6B column (Pharmacia Fine Chemicals). A gradient of0.15-0.65 M
NaCl in 0.025 M Bis Tris, 0.01 M EDTA, pH 5.9, was applied using a gradient maker (Phar-
macia Fine Chemicals) with 2.5 bed volumes in each chamber, at a flow rate of 8 ml/h. Frac-
tions containing only MSP were identified by SDS-PAGE, pooled, and filter concentrated
on ice with an Amicon Corp. filter unit using a filter with a nominal mot wt limit of 30,000.
Mass ofMSP.
￿
A BCA protein assay (Pierce Chemical Co., Rockford, IL) was used to de-
termine MSP mass, using BSA in BEN as a standard. Before analysis of mass, MSP was
dialyzed at VC overnight in a Spectrapor dialysis membrane with a 5-6,000 mol wt cut-off
against 1 L of BEN.
Purity ofMSP
￿
The purity of MSP was assessed by SDS-PAGE by applying 40 ug ofpurified
MSP to a 12.5% gel and staining with Coomassie Brilliant Blue R, and by applying 10 leg
of purified MSP to a 12.5% gel and silver staining (21).BLANDER AND HORWITZ
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Proteolytic Activity ofMSP.
￿
A colorimetric assay was used to determine the proteolytic ac-
tivity of MSP, with hide powder azure as the substrate and trypsin as the standard. Hide
powder azure(50 mg) was dissolved in 2 ml diluting buffer consisting of 0.1 M sodium phos-
phate, 0.001 M zinc sulfate, 0.02% sodium azide, pH 6.0. Dilutions of MSP and trypsin
dialyzed to diluting buffer, or diluting buffer alone as a blank, were added in 200-1.d aliquots
to the hide powder azure mix, and the mixture was rotated at 140 rpm at 37'C for 30 min.
The mixture was then chilled to 4°C to stop the reaction and subjected to centrifugation
at 1,400 g for 10 min at VC . The colored supernatant solution was aspirated, and the OD
read at 595 nm on an ultrospec 4050 spectrophotometer (LKB Instruments, Inc., Gaithers-
burg, MD), setting the OD of the blank to zero. A standard curve of proteolytic activity
(OD) versus mass for trypsin was constructed. One tryptic unit (TU) was defined as the pro-
teolytic activity of 1 lcg of trypsin. The proteolytic activity of MSP was derived from the
standard curve. The experiment was performed in duplicate.
Immunization of Guinea Pigs with MSP.
￿
MSP was dialyzed at 4°C overnight in a dialysis
membrane with a 6-8,000 mol wt cut-off against 1 L normal saline and mixed with CFA
adjuvant (Difco Laboratories) for the first injection, or IFA adjuvant (Sigma Chemical Co.)
for the second injection 3 wk later. The injection sites of the guinea pigs were washed with
70% ethanol and the animals were then injected subcutaneously with 40, 10, 2.5, or 0.6 Rg
ofMSP in a total volume of 2001al. Control animals were sham immunized at the same time
with normal saline only in CFA (first injection) or in IFA (second injection). One group of
animals immunized with 401ig of MSP in CFA was monitored daily for 5 d for fever, weight
loss, or signs of illness.
Immunization of Guinea Pigs with a Sublethal Dose ofL. pneumophila.
￿
Guinea pigs were im-
munized by exposure to aerosols of bacteria in the same lucite aerosol chamber described
in detail in a previous study (15). Guinea pigs were immunized with an aerosol generated
from a 10-ml suspension of L. pneumophila containing 2.5 x 107 CFU/ml.
ELISAfor Antibody to MSP.
￿
The humoral immune response of guinea pigs to MSP was
assessed by an ELISA assay. MSP in BEN was dialyzed at VC in a dialysis membrane with
a 6-8,000 mol wt cut-off against 1 L of0.01 M Tris, 0.1 M NaCl, 0 .0270 sodium azide, pH
7.2, diluted to a concentration of 5 jAg/ml in this buffer, and applied (50 ul/well) to Nunc-
Immuno Plates (Nunc Products, Thousand Oaks, CA). The plates were covered with an ace-
tate plate sealer (Flow Laboratories Inc., McClean, VA), incubated overnight at room tem-
perature, and stored at 4°C. The plates were washed five times with 0.01 M Tris, 0.1 M NaCl,
3% BSA, 0.02% sodium azide, pH 7 .5 (TNB), blocked with this buffer for 1 h, and tapped
dry. Guinea pig sera were diluted from 1 :8 to 1 :2048 in TNB, 50 h.l of each dilution was
added per well, and the plates were incubated for 1 h at room temperature with gentle shaking.
The plates were washed five times with TNB, tapped dry, and 50 hl of a 1 :1,000 dilution
ofalkaline phosphatase-conjugated goat anti-guinea pig IgG (whole molecule) (Sigma Chem-
ical Co.) was added per well. The plates were incubated for 1 h at room temperature with
gentle shaking, washed five times with TNB, and tapped dry. A reaction mix containing one
p-nitrophenyl phosphate tablet per 5 ml of 20% diethanolamine was prepared with an alka-
line phosphatase substrate kit (Bio-Rad Laboratories, Richmond, CA), and 125 hl added
per well for 15 min. Blank wells were treated with reaction mix only. The reaction was halted
with 50 Al per well of 0.6 M NaOH. The OD of wells was read at 405 nm on a Titertek
Multiskan (Flow Laboratories) and a corrected OD was calculated by subtracting the mean
of the OD of the blank wells from the OD of each experimental well. The threshold above
which titers were considered positive was established in three independent experiments by
measuring the OD ofthree different categories ofcontrol wells in each experiment. The con-
trol wells contained (a) MSP; no primary antibody; and conjugated antibody; (b) no MSP;
primary antibody (six different sera tested) diluted from 1 :32 to 1 :1,024; and conjugated
antibody; or (c) no MSP; no primary antibody; and conjugated antibody. For each of the
three categories of control wells, a value equal to the mean of the corrected OD readings
plus two times the standard deviation was calculated in each of the three experiments. The
mean of these nine values was designated as the threshold, and experimental measurements
abovethis threshold were considered positive. The titer of each animal's serum was expressed
as the reciprocal of the highest dilution yielding a positive measurement. Negative controls694
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were included on each experimental plate to monitor nonspecific reactions and positive con-
trols were included to allow comparisons among plates. All sera were tested in duplicate,
and the geometric mean of the reciprocal titers was calculated.
Cutaneous Delayed-type Hypersensitivity Assay.
￿
Guinea pigs were shaved over the back and
flank, and administered 100 ,u1 of various concentrations of MSP diluted in EYB, and 100
j1 of control buffer (EYB) intradermally. The diameters of erythema and induration were
measured at 24 h and 48 h after injection.
Lymphocyte Proliferation Assay.
￿
Splenic lymphocytes from guinea pigs immunized by injec-
tion with MSP or by sublethal infection, or from control guinea pigs, were obtained and
purified, incubated with MSP in triplicate microtest wells for 2 d, and then tested for their
capacity to incorporate [3H]thymidine as described (15).
Studies of Protective Immunity.
￿
Guinea pigs immunized with MSP and sham-immunized
control guinea pigs were challenged 3 wk after the second immunization with a lethal aero-
solized dose (LD) ofL. pneumophila . This dose, which was generated from a 10-ml suspension
ofL. pneumophila containing 2.5 x 108 CFU/ml, was the lowest dose that consistently resulted
in the death of nonimmunized guinea pigs, and it was determined as previously described
(15). In the first three experiments, the animals were challenged with 1 LD, and in the last
two experiments, the animals were challenged with 2 LD. After a 7-d observation period,
the survivors were quantitated, and differences in survival between immunized and control
animals were evaluated by the Fisher's exact test, two-tailed.
Quantitation ofL. pneumophila in Pulmonary Tissue.
￿
In two independent experiments, guinea
pigs were immunized with MSP at 3-wk intervals or sham immunized (controls), as described
above. 3 wk after the second immunization, the guinea pigs were challenged with 1 LD. At
various time points 1-72 h after challenge, one immunized and one control animal were killed
by hypercarbia. The animals were soaked first in 7 x cleaning solution (Linbro Chemical
Co., New Haven, CT) and second in 70° Jo ethanol to decontaminate their skin, and then
the right lung of each animal was removed by sterile technique. Each lung was placed in
10 ml of sterile EYB and ground thoroughly with a mortar and pestle as described (13). CFU
in each lung was determined by plating dilutions ofthis lung suspension in triplicate on CYEA.
The lung suspension was also cultured on sheep blood agar and CYEA without cysteine to
check for the presence ofcontaminating bacteria; none ofthe lungs were contaminated with
other bacteria.
Results
Purification ofMSP .
￿
We purified MSP by a three-step process involving ammo-
nium sulfate precipitation, molecular sieve chromatography, and ion-exchange chro-
matography. To assess the purity of MSP, we examined it by SDS-PAGE, loading
40 /Ag on a gel and staining with Coomassie Blue (Fig. 1), and loading 10 ug on
a gel and silver staining (19). By both techniques, we obtained a single band of39,000
apparent mol wt, suggesting a high degree of purity.
We assayed proteolytic activity at each step of the purification process (Table 1).
The proteolytic activity per mass increased from 0.021 TU/p,g in the unconcentrated
supernatant to 1.6 TU/,ug after ion-exchange chromatography, the final step in
purification. The amount of proteolytic activity after ion-exchange chromatography
indicated a 20% yield from the initial amount of proteolytic activity in the uncon-
centrated supernatant.
Subcutaneously Administered MSP Is Nonlethal and Nontoxic to Guinea Pigs.
￿
In five in-
dependent experiments, no animals died from subcutaneous immunization with MSP
in CFA or IFA. Moreover, none of six other animals immunized subcutaneously
with 40 hg ofMSP in CFA and then monitored closely for 5 d exhibited fever, weight
loss, or observable signs of illness.
Splenic Lymphocytesfrom Guinea Pigs Immunized with Either a Sublethal Aerosol Dose ofBLANDER AND HORWITZ
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FIGURE 1 .
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Purification ofMSP . MSP was isolated from broth cul-
ture as described in the text, andpreparations were examined by SDS-
PAGE aftereach sequential stage of the purification process : ammo-
nium sulfate precipitation (lane B),molecular sievechromatography
(lane C), and ion-exchange chromatography (lane D). Lane A con-
tains molecular weight standards (bovinealbumin, 66,000; ovalbumin,
45,000; glyceraldehyde-3-phosphate dehydrogenase 36,000 ; carbonic
anhydrase, 29,000; trypsinogen, 24,000 ; trypsin inhibitor 20,100) .
L . pneumophila or MSP Proliferate in Response to MSP .
￿
To determine if a population
of splenic lymphocytes from immunized guinea pigs recognize MSP, we examined
lymphocyte proliferative responses of immunized and control guinea pigs to this
molecule . In three experiments (Table II, part 1), we compared four animals im-
munizedwith a sublethal aerosol dose ofL. pneumophila with three control animals,
and in four experiments (Table II, part II), we compared four animals immunized
with MSP with four control animals . We performed the lymphocyte proliferation
assay 3-5 wk after sublethal dose immunization, and 4wk after the second immuni-
zation with MSP
Immunized animalsexhibited greaterlymphocyte proliferative responses to MSP
than control animals(Table II). Threeoffour guinea pigs immunizedwith asublethal
aerosol dose ofL . pneumophila (Table II, part I) and all four guinea pigs immunized
with MSP (Table II, part II) exhibited a higher stimulation index than their con-
TABLE I
Proteolytic Activity at Stages in the Purification ofMSP
MSP ofL . pneumophilawas purified from unconcentrated culture supernatant as described in
the text . At each stage in the purification process, the mass of the preparation was measured
by theBCA protein assayand the proteolytic activity was determined by the hide powder azure
assay .
Purification stage Protein
#9
Specific
proteolytic
activity
TUlctg
Total
proteolytic
activity
TU
Recovery
1 . Unconcentrated
culture supernatant 840,000 0.021 17,640 100
2 . Ammonium sulfate
precipitation 7,300 1 .02 7,446 42
3 . Gel permeation
chromatography 3,367 1 .3 4,377 25
4 . Ion-exchange
chromatography 2,150 1 .6 3,440 20696
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TABLE II
Lymphocytesfrom Guinea Pigs Immunized with either a Sublethal
Aerosol Dose of L. pneumophila or MSP Proliferate in Response to MSP
Stimulation indices' (SI)
Immunized MSP MSP
Exp.
￿
guinea pigs
￿
(0.5 ug/ml)
￿
(0.05 ug/ml)
I . Guinea pigs immunized with a sublethal aerosol dose of L. pneumophilia
A
B
C
Mean ±SEM
￿
1 .7±0.2
￿
1 .4±0.1
p1
￿
<0.2
￿
<0.2
II. Guinea pigs immunized with MSP
D
E
F
G
Mean ± SEM
￿
18.7 ± 3.0
￿
13 .3 ± 3.2
￿
8.2 ± 3.2
Control
guinea pigs
D
￿
D2
￿
-
￿
1 .0
￿
1 .0
E
￿
E2
￿
-
￿
1 .2
￿
1 .1
F
￿
F2
￿
7.7
￿
5.5
￿
1 .6
G
￿
G2
￿
1 .5
￿
3 .0
￿
1 .9
Mean ± SEM
￿
4.6 ± 3.1
￿
2 .7 ± 1 .0
￿
1 .4 ± 0.2
p1
￿
<0.05 <0.01 <0.05
In three independent experiments (A-C), guinea pigs were immunized with
a sublethal aerosol dose ofL. pneumophila or not immunized (controls). In four
independent experiments (D-G), guinea pigs were immunized subcutaneous-
ly with MSP (40 Ag in CFA followed 3 wk later by 40 ug in IFA) or sham-
immunized (buffer [saline] in CFAfollowed 3wk later by buffer in IFA). Splenic
lymphocytes were obtained 3-5 wk later and incubated (107/ml) in microtest
wells at 37°C for 2 d without antigen or with MSP at the concentrations indi-
cated. The lymphocytes were assayed for their capacity to incorporate
[3H]thymidine, and stimulation indices were calculated.
Stimulation index = (mean [3H]thymidine incorporation [cpm] of lympho-
cytes incubated with MSP)/(mean [3H]thymidine incorporation [cpm] oflym-
phocytes incubated without MSP).
1 p value for difference between SI of immunized and control guinea pigs by
1-test, two-tailed.
Al 9.2 2.0
Ill 2 .5 1.6
Cl 1 .0 1 .1
C2 6 .2 4.0
EM 4.7+ 1 .8 2.2+0.6
Control
guinea pigs
A2 2 .0 1 .4
B2 1 .3 1 .2
C3 1 .7 1.5
Immunized
guinea pigs
MSP
(5 pg/ml)
Stimulation indices"
MSP
(0 .5 jig/ml)
(SI)
MSP
(0.05 ug/ml)
DI - 17 .2 15.8
El - 13 .8 11 .1
F1 15.2 4.2 1 .5
G1 22.1 18.0 4.5BLANDER AND HORWITZ
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trols. The mean stimulation indices of sublethal dose-immunized guinea pigs in re-
sponse to 0.5 and 0.05 Ftg/ml MSP were 4.7 and 2.2, respectively, compared with
1.7 and 1.4 for control animals (Table II, part I). Although the mean stimulation
indices for the sublethal dose-immunized animalsin response to 0.5 and0.05 /Ag/ml
of MSP were 2.8 and 1.6 times those of controls, respectively, this difference did
not achieve significance by the t-test. The mean stimulation indicesofMSP-immunized
animalsranged from 8.2 to 18.7, dependingon the concentration ofMSP (0 .05-5 ttg/
ml). In contrast, the mean stimulation indices of control animals ranged from 1.4
to 4.6 (Table 11, part 11). These differences were highly significant by the t-test (p
values ranged from p < 0.01 to p < 0.05; Table II, part II).
Guinea Pigs Immunized with Either a SublethalAerosol Dose ofL. pneumophila or MSP
Develop CutaneousDelayed-type Hypersensitivityto MSP. To determineif sublethaldose-
immunized or MSP-immunizedguinea pigs develop acutaneous delayed-type hyper-
sensitivity response to MSP, we injected them intradermally with various concen-
trations of MSP 3 wk afterimmunization and measured theextent of erythema and
induration at theskin test sites. Both sublethal dose-immunized and MSP-immunized
animals consistently had greater mean areas of erythema and induration than con-
trol animals (Table III).
Sublethal dose-immunized animals exhibited mean diameters of erythema and
induration of 15.2 and 7.8 mm, respectively, 24 h afterintradermal injectionof MSP,
compared with 2.0 and 0.0 mm, respectively, in control animals (Table III, Exp.
A). Mean diameters oferythema andinduration afterintradermalinjection ofbuffer
control were minimal in both immunized and control animals.
MSP-immunized animals were skin tested at 24 and 48 h after injection with 100
ul of 1 Wg/ml of MSP (Table 111, Exp. B) . At 24 h, MSP-immunized animals ex-
hibited mean diameters of erythema and induration of 17 .2 and 6.0 mm, respec-
tively, compared with 3.3 and 1.0 mm, respectively, in control animals. By 48 h,
skin responses in both groups of animals had waned, but the stronger responses of
animals in the immunized group were still evident.
MSP-immunized and control animalswere also skin tested with 100-,l injections
of MSP over a range of concentrations (0.5, 5, and 50 Ag/ml) (Table III, Exp. C).
Both groups of animals exhibited dose-dependent skin responses, but at all three
concentrations of MSP, theMSP-immunized animalsexhibited much greaterareas
of erythema and induration than control animals.
In both types of experiments with MSP-immunized animals, intradermal injec-
tion of diluting buffer did not produce either erythema or induration in either im-
munized or control animals (Table III).
MSP-immunizedbut not Sublethal Dose-immunized Guinea Pigs Develop a Humoral Im-
mune ResponsetoMSP. To determine if guinea pigs immunizedwith either asublethal
aerosol dose of L. pneumophila or MSP develop ahumoralimmune response to MSP,
we assayed anti-MSP antibody by an ELISA assay, using purified MSP as the cap-
ture antigen, guinea pig sera as the source of primary antibody, and alkaline phos-
phatase-conjugated goat anti-guinea pig IgG as the secondary antibody (Fig. 2).
None of the sublethal dose-immunized guinea pigs developed a humoral immune
response to MSP; all four such animals and three control animals had reciprocal
antibody titers of <8 (Fig. 2 A). In contrast, all six MSP-immunized guinea pigs
developed a strong humoral response to MSP; theirtiters ranged from 45 to >2,048,698
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TABLE III
Guinea Pigs Immunized with either a Sublethal Aerosol Dose of L. pneumophila or MSP
Develop Cutaneous Delayed-type Hypersensitivity to MSP
In oneexperiment (A), guinea pigs were immunized with a sublethal aerosol dose ofL. pneumophila or they
were not immunized (controls). In two other independent experiments (B and C), guinea pigs were im-
munized subcutaneously with MSP or sham immunized as in Table II. 3 wk later, all animals were skin
tested with an intradermal injection of 100 Kl of the indicated concentration of MSP, and the extent of
erythema and induration was measured 24 h later in Exps. A and C and both 24 and 48 h later in experi-
ment B, Data are the mean t SD of the extent of erythema and induration for each group of animals .
* SI = stimulation index = [mean skin reactivity (mm) of immunized guinea pigs]/[mean skin reactivity
(mm) of control guinea pigs].
while five of six control guinea pigs had titers of <16 (Fig. 2 B). A single control
guinea pig exhibited a high titer to MSP; this was possibly due to the presence of
a crossreactive antibody in this animal.
Thus, while MSP-immunized animals developed both a cell-mediated and hu-
moral immune response to MSP, the sublethal dose-immunized animals developed
only a cell-mediated immune response.
Guinea Pigs Immunized with MSP Are Protected against Lethal Aerosol Challenge with
L. pneumophila.
￿
To determine if guinea pigs immunized with MSP are protected
II. Guinea pigs immunized
SI (Induration)*
with MSP
00 -
1 .0 (24 h) 1 .0 (48 h) 0.0 (24 h) 0.0 (48 h)
MM
B Immunized 3 Erythema 17.2 ± 4.5 11 .8 ± 5.0 0.0 t 0.0 0.0 ± 0.0
Induration 6.0 ± 1 .0 1 .7 ± 2.9 0.0 t 0.0 0.0 t 0.0
Control 3 Erythema 3.3 f 2 .9 0.0 t 0.0 0.0 t 0.0 0.0 ± 0.0
Induration 1 .0 ± 1 .7 0 .0 ± 0.0 0.0 t 0.0 0.0 t 0.0
SI (Erythema)* 5 .2 00 - -
SI (Induration)* 6.0 00 - -
24 h
50 5 .0 0.5 0.0
mm
C Immunized 6 Erythema 23.3 ± 6 .2 14.2 ± 4.6 9.0 t 2.0 0.0 ± 0.0
Induration 13.0 t 8.4 6.8 t 4.7 3.5 t 3 .7 0.0 ± 0.0
Control 3 Erythema 8.3 t 3 .1 4.3 ± 0.6 0.0 ± 0.0 0.0 ± 0.0
Induration 0.0 f 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 t 0.0
SI (Erythema)* 2 .8 3.3 -
SI (Induration)* 00 00 -
Number Mean extent oferythema
Status of of guinea Skin to indicated
Exp. guinea pigs pigs reactions 1 .0 (24 h)
and induration in response
concentration of MSP (kg/ml)
0.0 (24 h)
mm
I. Guinea pigs immunized with a sublethal aerosol dose of L. pneumophila
A Immunized 3 Erythema 15 .2 ± 2.3 1 .0 ± 1 .7
Induration 7 .8 t 1 .0 0.0 ± 0.0
Control 3 Erythema 2.0 ± 2.0 1 .7 f 2.9
Induration 0.0 + 0.0 0.0 +_ 0.0
SI (Erythema)* 7.6 0.6BLANDER AND HORWITZ
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FIGURE 2.
￿
MSP-immunized but not sublethal
dose-immunized guineapigs develop a humoral
immune responseto MSP. In studies depicted in
A, four guinea pigs were immunized with a
sublethal dose of L. pneumophila and three con-
trol guinea pigs were not immunized. In studies
depicted in B, six guinea pigs were immunized
with MSP and six were sham immunized, as in
Table III. 3 wk later, serum was obtained from
each animal and assayed for antibody to MSP
by ELISA. All sera were tested in duplicate, and
the geometric mean of the reciprocal titers was
clultd. All dplittitrithiacaeucae
￿
ers wee wn one
Sublethal Dose-
￿
Control
￿
MSP-
￿
Control
￿
twofold dilution of each other. Immunized
￿
Guinea Pigs
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against lethal aerosol challenge, we immunized guinea pigs with 40 Fig of MSPtwice,
3 wk apart, and challenged them in five independent experiments. In the firstthree
experiments, we challenged 14 control and 15 MSP-immunized guinea pigs with
1 LD of L. pneumophila, and in the last two experiments, we challenged 12 control
and 11 MSP-immunized guinea pigs with 2 LD of L. pneumophila.
MSP immunization produced strong protective immunity in each of the 5 experi-
ments (Table IV). Whereas none (0%) of 26 control animals survived challenge in
the five experiments, 21 (81%) of 26 MSP-immunized animals survived challenge.
TABLE IV
Immunization of Guinea Pigs with MSP Induces Protective Immunity
Against Lethal Aerosol Challenge with Legionella pneumophila
In five independent experiments, guinea pigs were immunized subcutaneous-
ly with MSP or sham immunized as described in Table II. 3 wk later, the
animals were challenged with 1 LD of L. pneumophila (Exps. A, B, and C) or
2 LD (Exps. D and E), and survival was quantitated.
' Fisher's Exact Test, two-tailed.
Exp.
Status of
guinea pigs
Number guinea pigs
surviving per
number challenged
(percent survival) P.
A Control 0/5 (0)
Immunized 4/5(80) 0.05
B Control 0/5 (0)
Immunized 5/6 (83) 0.02
C Control 0/4(0)
Immunized 4/4(100) 0.03
D Control 0/6 (0)
Immunized 4/6 (67) 0.03
E Control 0/6(0)
Immunized 4/5 (80) 0 .02
Total Control 0/26(0)
Immunized 21/26(81) 7 x 10- t0
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2048
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" 512
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Thedifference in survival between MSP-immunized and control animalswas highly
significant (p = 7 x 10 1°, Fisher's exact test, two-tailed) .
Of the MSP-immunized animals challenged with 1 LD, 13 (87%) of 15 survived,
whereas of the MSP-immunized animals challenged with 2 LD, 8 (73%) of 11 sur-
vived. This difference was not statistically significant by the Fisher's exact test, two-
tailed.
Guinea pigs immunized with MSP first exhibited signs of illness, includingfever,
decreased activity, decreased feeding, and respiratory distress, 1 d after challenge,
butthey then recovered. Nonimmunized animalsfirst exhibitedthesesigns ofillness
2 d afterchallenge, but they didnot recover. All animals surviving by 7 d afterchal-
lenge recovered fully from earlier signs of disease.
Protection againstLethal Aerosol Challengewith L. pneumophilaby Immunization with MSP
is Dose-dependent. To determine iflower doses of MSP could induce protective im-
munity in guinea pigs, we immunized animals with 40, 10, 2.5, or 0.6 jug of MSP,
and then challenged them with 2 LD of L. pneumophila. As in previous studies, we
immunized all animals twice, 3 wk apart, and sham-immunized control animals.
We performed two independent experiments (Table V).
MSP induced protective immunity in dose-dependent fashion in both experiments.
Combining the results of the two experiments, 73% of 11 animals immunized with
40,ug MSP survived challenge, 58% of 12 animals immunized with 10 Fig MSP,
50% of 12 animals immunized with 2.5 p.g MSP, 25% of 12 animals immunized
with 0.6 Ftg MSP, and 0% of 12 sham-immunized animals (0 lAg MSP). The 40-jug
dose induced significant protection in both experiments, the 10- and 2.5-Ag doses
each induced significant protection in one of the two experiments, and the 0.6-wg
dose did not induce significant protection in either experiment. When the results
of both experiments were combined, the 40-, 10-, and 2.5-wg doses all produced
significant levels of protection with p = 0.0003, p = 0.005, and p = 0.01, respec-
tively, by the Fisher's exact test, two-tailed. Even the 0.6-hg dose, the lowest dose
TABLE V
Immunization of Guinea Pigs with Varying Doses of MSP Induces Dose-dependent
Protective Immunity to Lethal Aerosol Challenge with L. pneumophila
In two independent experiments, guinea pigs were immunized subcutaneously with MSP or sham immunized
as in Table II except that the dose of MSP ranged from 0.6 to 40 gg, as indicated . 3 wk later, the animals
were challenged with 2 LD of L. pneumophila.
p value for difference in survival between animals immunized with the indicated dose of MSP and control
animals by the Fisher's exact test, two-tailed.
Guinea pigs surviving:
Guinea pig MSP
Exp.
Per number
A Exp.
Per number
B
Per number
Total
status dose challenged Percent P' challenged Percent P` challenged Percent P"
#g
Immunized 40 4/6 67 0.03 4/5 80 0.02 8/11 73 0.0003
Immunized 10 2/6 33 0.5 5/6 83 0.02 7/12 58 0.005
Immunized 2.5 1/6 17 1 .0 5/6 83 0.02 6/12 50 0.01
Immunized 0.6 0/6 0 1 .0 3/6 50 0.09 3/12 25 0.1
Control 0.0 0/6 0 0/6 0 0/12 0BLANDER AND HORWITZ
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tested, appeared to induce some protection, but thelevelof significance was nothigh
(p = 0.1).
Guinea Pigs Immunizedwith MSPSuppress Multiplication ofL. pneumophila in the Lung.
To determinethe extent ofL. pneumophila multiplication in thelung ofMSP-immunized
guinea pigs, we challenged 5 MSP-immunized and five control guinea pigs with 1
LD of L. pneumophila, killed them 1-72 h later, and determined CFU of L. pneu-
mophila in the right lung. We performed two independent experiments (Fig. 3). At
1 h after aerosol exposure, immunized and control animals had similar numbers
of L. pneumophila in their lungs in both experiments. By 24 h, CFU markedly in-
creased (2 logs) in both immunized and control animals, but the rate of growth was
the same so that both groups had comparable numbers of bacteria in the lung at
this time point. Thereafter, CFU in immunized animals plateaued, whereas CFU
in controlanimalscontinuedto increase. By 4$ h, CFU of L. pneumophila in controls
was 0.6-0.7 logs greater than in immunized animals, and by 72 h, CFU of L. pneu-
mophila in controls was 1.4 logs greater than in immunized animals.
Discussion
We have demonstrated that immunization of guinea pigs with theMSP ofL. pneu-
mophila induces a highly significant level (p = 7 x 10-1°) of protective immunity
againstlethal challenge with an aerosolized dose ofL. pneumophila. Thelethal aerosol
doses used in this study were much higher than those likely to be encountered by
humans in nature. Remarkably, immunization with a single protein ofL. pneumophila
induces strong protective immunity against this complex intracellular parasite.
Previous studies from this laboratory have shown that immunization of guinea
Time after lethal challenge (h) Time after lethal challenge (h)
FIGURE 3 .
￿
In two independent experiments, MSP-immunized guinea pigs and controls were
challenged with one lethal dose of aerosolized L. pneumophila. At thetime points indicated, one
immunized and one control animal were killed. CFU ofL. pneumophila in the right lung of each
guinea pig was determined as described in the text. Each point represents the mean t SEM
of triplicate measurements of each lung.
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pigs by the respiratory route with a sublethal dose of L. pneumophila (15), or with
an avirulent mutant strain of L. pneumophila that survives but does not multiply in
human monocytes (16), induces protective immunity. The present study demonstrates
that immunization of guinea pigs by the subcutaneous route with MSP also can
induce protective immunity.
MSP is a very potent inducer of protective immunity against lethal aerosol chal-
lenge. As little as 2.5 p,g, injected twice over a 3 wk interval, was capable of inducing
a significant level of protective immunity against 2 LD of L. pneumophila (p = 0.01,
Fisher's exact test, two-tailed) and even two injections of 0.6 wg MSP appeared to
induce some protection. In this series of experiments, over the range 0.6 to 40 Ag
of MSP, two injections of 40 tag MSP gave the highest level of protection.
Guinea pigs immunized with MSP andthen challenged with alethal dose of aero-
solized L. pneumophila limited L. pneumophila multiplication in their lungs. In both
immunized and control animals, L. pneumophila multiplied in the lungs during the
first 24 h afterchallenge. Thereafter, CFU in thelungs ofcontrol animals continued
to increase, whileCFU in the lungs of immunized animals plateaued. These results
were similar to those obtained in studies of animals immunized with a sublethal
dose of L. pneumophila and control guinea pigs (15). These results suggest that pro-
tective immune defenses are marshalled during the first 24 h after challenge. This
time period correspondsroughly to that required forlymphokines to activate human
mononuclear phagocytes (6). Such activated monocytes and alveolar macrophages
strongly inhibit the intracellular multiplication of L. pneumophila (5-9).
Consistent with the idea that immunized guinea pigs marshall immune defenses
during the first 24 h after challenge, immunized but not control guinea pigs devel-
oped signs of illness during this period. This may reflect an early immune response
to L. pneumophila in immunized animals, who generally recovered from the infec-
tion. In contrast, control animals developed signs of illness later after challenge and
succumbed to the infection.
Both guinea pigs immunized with a sublethal dose of L. pneumophila and guinea
pigs immunized with MSP developed a cell-mediated immune response to MSP
However, only MSP-immunized animals developed a humoral immune response
to MSP. Both groups of immunized animals exhibited strong protective immunity.
This suggests that antibody against MSP is not important to host defense but that
a cell-mediated immune response to MSP may be. Although previous studies indi-
cate that cell-mediated immunity is of primary importance to host defense against
L. pneumophila after natural infection, it is possible that anti-MSP antibody is also
playing a role in the protective immunity induced by MSP immunization.
That both sublethal dose-immunized and MSP-immunized guinea pigs develop
a cell-mediated immune response to MSP, but only MSP-immunized animals de-
velop a humoral immune response to this molecule, suggests the possibility that an-
tigen processing of MSP differs according to how the molecule is presented to the
immune system. In guinea pigs immunized by sublethal dose, MSP produced by
L. pneumophilawithin mononuclearphagocytes may be processedintracellularly such
that only smalllinear determinants arepresented to lymphocytes. Such determinants
may induce cellular immune responses, which are frequently directed toward un-
folded linear epitopes, but not humoral immune responses, which are frequently
directed toward a tertiary structure of nondenatured antigen (22-24). In contrast,BLANDER AND HORWITZ
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in guinea pigs immunized subcutaneously with MSP, both primary and tertiary
structures may be presented to lymphocytes, allowing both cell-mediated and hu-
moral immune responses.
If, indeed, native or processed MSP is released by mononuclear phagocytes or
presented on their surface, then the immune system would have a mechanism for
detecting intracellular L. pneumophila. Thus, immune lymphocytes that recognize
MSP epitopes might proliferate and release lymphokines such as IFN-'Y that are
capable of activating the infected mononuclear phagocyte and endowing it with the
capacity to inhibitthe multiplication of intracellular L. pneumophila (8, 9). By analogy,
secretorymoleculesofintracellular pathogens may in general allowtheimmune system
to detect parasites sequestered in an intracellular site and therebyto defend the host
against them. Along these lines, the intracellular bacterial pathogens Listeria
monocytogenes and Mycobacterium tuberculosis release molecules into broth culture that
stimulate a cellular immune response (25, 26).
The finding that the MSP is capable of inducing protective immunity against
L. pneumophila infection was arrived at by (a) establishing an animal model suitable
for studying cell-mediated and protective immunity (15); (b)systematically examining
L. pneumophila molecules for their capacity to induce cell-mediated immunity (17);
and (c) testing such immunostimulatory molecules fortheir capacity to induce pro-
tective immunity. This approach might similarly reveal protective antigens of other
intracellular pathogens for which cell-mediated immunity plays an important role
in host defense.
Avaccine againstan intracellular pathogen consisting ofasecretorymolecule poten-
tially hastwo important advantages over a conventional vaccine, consisting of whole
organisms or their surface components. First, it may more readily allow the im-
mune system to detect pathogens sequestered in an intracellular site, as noted above.
Second, it should be less likely to induce antibody to surfacemolecules ofthe pathogen.
Such antibody might promote uptake of the pathogen into mononuclearphagocytes,
where the organism multiplies, and thereby be counter-productive to host defense.
Summary
We have examined the capacity of the majorsecretory protein (MSP) ofLegionella
pneumophila to induce humoral, cell-mediated, and protective immunity in aguinea
pig model of Legionnaires' disease. MSP was purified to homogeneity by ammo-
nium sulfate precipitation, molecularsievechromatography, andion-exchange chro-
matography. The purified MSP was nonlethal and nontoxic to guinea pigs upon
subcutaneous administration.
Guinea pigs immunized with a sublethal dose of aerosolized L. pneumophila or a
subcutaneous dose of MSP developed a strong cell-mediated immune response to
MSP. Such guinea pigs exhibited marked splenic lymphocyte proliferation and cu-
taneousdelayed-type hypersensitivity to MSP in comparison with control animals.
Guinea pigs immunized with MSP also developed a strong humoral immune re-
sponse to MSP, as assayed by an ELISA. The median reciprocal antibody titerwas
362 (range 45 to >2,048) for immunized animals compared with <8 for controls.
In contrast, guinea pigs immunized with a sublethal dose of L. pneumophila failed
to develop anti-MSP antibody.
Guinea pigs immunized with MSP and then challenged with a lethal aerosol dose704
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of L. pneumophila exhibited highly significant protective immunity in each of five
consecutive experiments. MSP induced protective immunity in dose-dependent
fashion (40>10>2.5>0.6 Ag MSP); vaccination with two doses of as little as 2.5 1~g
MSP induced significant protective immunity (p = 0.01, Fisher's Exact Test, two-
tailed). Altogether, 21 (81%) of 26 animals immunized with 40 lAg MSP survived
challenge compared with 0 (0%) of 26 sham-immunized control animals (p = 7
x 10 - x°, Fisher's Exact Test, two-tailed). MSP-immunized but not control guinea
pigs were able to limit L. pneumophila multiplication in their lungs.
This study demonstrates that (a) guinea pigs sublethally infected with L. pneu-
mophila develop a strong cell-mediated immune response to MSP; (b) guinea pigs
immunized with MSP develop a strong humoral and cell-mediated immune response
to MSP; (c) guinea pigs immunized with MSP develop a very high level of protective
immunity to lethal aerosol challenge with L. pneumophila; and (d) MSP-immunized
animals are able to limit L. pneumophila multiplication in their lungs.
MSP, an extracellular protein ofan intracellular pathogen, has potential as a vac-
cine for the prevention of Legionnaires' disease. Secretory molecules of other intra-
cellular pathogens may also have vaccine potential.
We are grateful to Ms. Debora Gloria and Ms. Barbara Jane Dillon for expert technical as-
sistance.
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